链脲佐菌素诱导小鼠糖尿病肾病模型的建立(2)
參考文献
Lee， J.Y.， et al.， Adiponectin for the treatment of diabetic nephropathy.Korean J Intern Med，2019.34(3)： p.480-491.
Gan， L.M.， et al.， Intradermal delivery of modified mRNA encoding VEGF-A in patients with type2diabetes.Nat Commun，2019.10(1)： p.871.
Krolewski， A.S.， et al.， Fast renal decline to end-stage renal disease： an unrecognized feature of nephropathy in diabetes.Kidney Int，2017.91(6)： p.1300-1311.
Dal Monte， M.， et al.， Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.J Cell Mol Med，2019.23(2)： p.1034-1049.
Kitada， M.， Y.Ogura， and D.Koya， Rodent models of diabetic nephropathy： their utility and limitations.Int J Nephrol Renovasc Dis，2016.9： p.279-290.
Rodionov， R.N.， et al.， ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.Atheroscler Suppl，2017.30： p.319-325.
Tian， J.， et al.， Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Treatment of Type2Diabetes： A Systematic Review and Meta-analysis.Diabetes Obes Metab，2019.
Ma， T.， et al.，4-O-methylhonokiol ameliorates type2diabetes-induced nephropathy in mice likely by activation of AMPK-mediated fatty acid oxidation and Nrf2-mediated anti-oxidative stress.Toxicol Appl Pharmacol，2019.370： p.93-105.
Subramaniam， A.， et al.， The Nile Rat (Arvicanthis niloticus) as a Superior Carbohydrate-Sensitive Model for Type2Diabetes Mellitus (T2DM).Nutrients，2018.10(2).
Gandhi， J.， et al.， Genitourinary Complications of Diabetes Mellitus： An Overview of Pathogenesis， Evaluation， and Management.Curr Diabetes Rev，2017.13(5)： p.498-518.
Zhu， J.， et al.， Predictive Model for Estimating the Cost of Incident Diabetes Complications.Diabetes Technol Ther，2016.18(10)： p.625-634., 百拇医药(王友娣 王李卓 高家林)
Lee， J.Y.， et al.， Adiponectin for the treatment of diabetic nephropathy.Korean J Intern Med，2019.34(3)： p.480-491.
Gan， L.M.， et al.， Intradermal delivery of modified mRNA encoding VEGF-A in patients with type2diabetes.Nat Commun，2019.10(1)： p.871.
Krolewski， A.S.， et al.， Fast renal decline to end-stage renal disease： an unrecognized feature of nephropathy in diabetes.Kidney Int，2017.91(6)： p.1300-1311.
Dal Monte， M.， et al.， Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.J Cell Mol Med，2019.23(2)： p.1034-1049.
Kitada， M.， Y.Ogura， and D.Koya， Rodent models of diabetic nephropathy： their utility and limitations.Int J Nephrol Renovasc Dis，2016.9： p.279-290.
Rodionov， R.N.， et al.， ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.Atheroscler Suppl，2017.30： p.319-325.
Tian， J.， et al.， Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Treatment of Type2Diabetes： A Systematic Review and Meta-analysis.Diabetes Obes Metab，2019.
Ma， T.， et al.，4-O-methylhonokiol ameliorates type2diabetes-induced nephropathy in mice likely by activation of AMPK-mediated fatty acid oxidation and Nrf2-mediated anti-oxidative stress.Toxicol Appl Pharmacol，2019.370： p.93-105.
Subramaniam， A.， et al.， The Nile Rat (Arvicanthis niloticus) as a Superior Carbohydrate-Sensitive Model for Type2Diabetes Mellitus (T2DM).Nutrients，2018.10(2).
Gandhi， J.， et al.， Genitourinary Complications of Diabetes Mellitus： An Overview of Pathogenesis， Evaluation， and Management.Curr Diabetes Rev，2017.13(5)： p.498-518.
Zhu， J.， et al.， Predictive Model for Estimating the Cost of Incident Diabetes Complications.Diabetes Technol Ther，2016.18(10)： p.625-634., 百拇医药(王友娣 王李卓 高家林)